A detailed history of Nantahala Capital Management, LLC transactions in Uni Qure N.V. stock. As of the latest transaction made, Nantahala Capital Management, LLC holds 2,781,013 shares of QURE stock, worth $47.2 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares
2,781,013
Previous 2,650,472 4.93%
Holding current value
$47.2 Million
Previous $11.9 Million 15.46%
% of portfolio
0.81%
Previous 0.79%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.78 - $10.12 $493,444 - $1.32 Million
130,541 Added 4.93%
2,781,013 $13.7 Million
Q2 2024

Aug 14, 2024

SELL
$4.39 - $5.43 $1.92 Million - $2.38 Million
-437,610 Reduced 14.17%
2,650,472 $11.9 Million
Q1 2024

May 15, 2024

BUY
$4.82 - $6.93 $626,865 - $901,281
130,055 Added 4.4%
3,088,082 $16.1 Million
Q4 2023

Feb 14, 2024

SELL
$5.63 - $8.27 $370,296 - $543,934
-65,772 Reduced 2.18%
2,958,027 $20 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $11.83 $1.17 Million - $2.07 Million
174,815 Added 6.14%
3,023,799 $20.3 Million
Q2 2023

Aug 14, 2023

SELL
$11.12 - $22.2 $2.46 Million - $4.91 Million
-221,377 Reduced 7.21%
2,848,984 $32.6 Million
Q1 2023

May 15, 2023

BUY
$18.7 - $23.07 $6.92 Million - $8.54 Million
370,122 Added 13.71%
3,070,361 $61.8 Million
Q4 2022

Feb 14, 2023

SELL
$18.12 - $27.32 $3.65 Million - $5.51 Million
-201,690 Reduced 6.95%
2,700,239 $61.2 Million
Q3 2022

Nov 10, 2022

SELL
$16.98 - $25.54 $3.21 Million - $4.82 Million
-188,828 Reduced 6.11%
2,901,929 $54.4 Million
Q2 2022

Aug 15, 2022

BUY
$13.15 - $20.45 $3.67 Million - $5.71 Million
279,298 Added 9.93%
3,090,757 $57.6 Million
Q1 2022

May 13, 2022

BUY
$14.54 - $21.5 $6.52 Million - $9.64 Million
448,146 Added 18.96%
2,811,459 $50.8 Million
Q4 2021

Feb 14, 2022

BUY
$20.24 - $36.01 $12.2 Million - $21.8 Million
604,095 Added 34.34%
2,363,313 $49 Million
Q3 2021

Nov 15, 2021

SELL
$26.01 - $38.22 $92,283 - $135,604
-3,548 Reduced 0.2%
1,759,218 $56.3 Million
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $2.69 Million - $3.34 Million
89,875 Added 5.37%
1,762,766 $54.3 Million
Q1 2021

May 14, 2021

BUY
$29.24 - $42.03 $1.06 Million - $1.53 Million
36,352 Added 2.22%
1,672,891 $56.4 Million
Q4 2020

Feb 16, 2021

BUY
$35.35 - $50.67 $1.88 Million - $2.69 Million
53,181 Added 3.36%
1,636,539 $59.1 Million
Q3 2020

Nov 16, 2020

BUY
$35.98 - $47.66 $547,219 - $724,860
15,209 Added 0.97%
1,583,358 $58.3 Million
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $6.36 Million - $9.56 Million
-141,123 Reduced 8.26%
1,568,149 $70.7 Million
Q1 2020

May 14, 2020

BUY
$40.01 - $73.97 $15.1 Million - $27.9 Million
377,434 Added 28.34%
1,709,272 $81.1 Million
Q4 2019

Feb 14, 2020

SELL
$37.13 - $74.62 $23.7 Million - $47.5 Million
-637,000 Reduced 32.35%
1,331,838 $95.4 Million
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $20.7 Million - $40.4 Million
526,378 Added 36.49%
1,968,838 $77.5 Million
Q2 2019

Aug 14, 2019

SELL
$52.76 - $82.19 $4.02 Million - $6.27 Million
-76,230 Reduced 5.02%
1,442,460 $113 Million
Q1 2019

May 15, 2019

SELL
$27.39 - $68.41 $26.3 Million - $65.7 Million
-959,977 Reduced 38.73%
1,518,690 $90.6 Million
Q4 2018

Feb 14, 2019

BUY
$22.8 - $33.93 $13.6 Million - $20.2 Million
596,196 Added 31.67%
2,478,667 $71.4 Million
Q3 2018

Nov 14, 2018

BUY
$29.75 - $43.08 $3.75 Million - $5.43 Million
126,032 Added 7.18%
1,882,471 $68.5 Million
Q2 2018

Aug 14, 2018

SELL
$21.96 - $39.94 $1.83 Million - $3.33 Million
-83,335 Reduced 4.53%
1,756,439 $66.4 Million
Q1 2018

May 15, 2018

SELL
$17.1 - $26.61 $703,083 - $1.09 Million
-41,116 Reduced 2.19%
1,839,774 $43.2 Million
Q4 2017

Feb 14, 2018

BUY
$9.47 - $19.59 $7.21 Million - $14.9 Million
761,007 Added 67.95%
1,880,890 $36.8 Million
Q3 2017

Nov 14, 2017

BUY
$7.7 - $9.6 $8.62 Million - $10.8 Million
1,119,883
1,119,883 $10.8 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $793M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Nantahala Capital Management, LLC Portfolio

Follow Nantahala Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.